Market Research Reports and Industry Reports

EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

Summary

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the forecast for the total prevalent cases (including both diagnosed and undiagnosed) as well as the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, late wet AMD, and large drusen in the 7MM.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

The total prevalent cases of AMD in the 7MM will increase from 71,787,702 cases in 2016 to 82,997,296 cases in 2026, at an Annual Growth Rate (AGR) of 1.56% over the forecast period. Throughout the forecast period, Japan will have the highest number of total prevalent cases of AMD, followed by Italy. The total prevalent cases of AMD in Japan and Italy combined will make up approximately 39.28% of the total prevalent cases of AMD in the 7MM. GlobalData epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.

Scope

- The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors and global trends of AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report also includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets. GlobalData epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older). Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen (125 m) segmented by sex and age (ages 50 years and older) in these markets.
- The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The AMD EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.
- Understand magnitude of AMD population by type.

2
1.List of Tables 4
1.2 List of Figures 4
2 Age-Related Macular Degeneration: Executive Summary 5
2.Related Reports 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.4 Forecast Methodology 10
3.4.Sources 12
3.4.2 Forecast Assumptions and Methods 13
3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 14
3.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen 18
3.5 Epidemiological Forecast for AMD (2016-2026) 20
3.5.Total Prevalent Cases of AMD 20
3.5.2 Age-Specific Total Prevalent Cases of AMD 20
3.5.3 Sex-Specific Total Prevalent Cases of AMD 22
3.5.4 Total Prevalent Cases of Early AMD 22
3.5.5 Total Prevalent Cases of Late AMD 23
3.5.6 Total Prevalent Cases of Late Dry AMD 24
3.5.7 Total Prevalent Cases of Late Wet AMD 24
3.5.8 Total Prevalent Cases of Large Drusen 25
3.5.9 Diagnosed Incident Cases of AMD 26
3.5.10 Age-Specific Diagnosed Incident Cases of AMD 27
3.5.1Sex-Specific Diagnosed Incident Cases of AMD 27
3.5.12 Diagnosed Incident Cases of Early AMD 28
3.5.13 Diagnosed Incident Cases of Late AMD 29
3.5.14 Diagnosed Incident Cases of Late Dry AMD 30
3.5.15 Diagnosed Incident Cases of Late Wet AMD 30
3.5.16 Diagnosed Incident Cases of Large Drusen 31
3.6 Discussion 32
3.6.Epidemiological Forecast Insight 32
3.6.2 Limitations of the Analysis 32
3.6.3 Strengths of the Analysis 33
4 Appendix 34
4.Bibliography 34
4.2 About the Authors 36
4.2.Epidemiologist 36
4.2.2 Reviewers 36
4.2.3 Global Director of Therapy Analysis and Epidemiology 37
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 37
4.3 About GlobalData 38
4.4 Contact Us 38
4.5 Disclaimer 38

List Of Tables

1.1 List of Tables
Table 1: Risk Factors and Comorbid Conditions Associated with AMD 9
Table 2: Classification of AMD 11
Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 20
Table 4: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 23
Table 5: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 23
Table 6: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 24
Table 7: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages 50 Years, Selected Years 2016-2026 25
Table 8: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 25
Table 9: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 26
Table 10: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 29
Table 11: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 29
Table 12: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 30
Table 13: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 31
Table 14: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages 50 Years, N, Selected Years 2016-2026 31

EpiCast Report: Uveitis - Epidemiology Forecast to 2026

EpiCast Report: Uveitis - Epidemiology Forecast to 2026Uveitis is the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such

USD 3995View Report

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in

USD 3995View Report

EpiCast Report: Uveitis - Epidemiology Forecast to 2026

EpiCast Report: Uveitis - Epidemiology Forecast to 2026Uveitis is the inflammation of the uveal tract (iris, ciliary body, and choroid), but can also cause the inflammation of nearby tissues, such

USD 3995View Report

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026

EpiCast Report: Prostate Cancer - Epidemiology Forecast to 2026Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in

USD 3995View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3995
  • Site Licence    USD 7990
  • Enterprise Wide Licence    USD 11985
$ 3995

Reports Details

Published Date : Nov 2017
No. of Pages :38
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube